Literature DB >> 31662566

Level and Value of T Cell-derived Circulating Microparticles in Liver Cirrhosis Patients.

Chih-Hung Chen1, Chia-Lo Chang2, Kuan-Hung Chen3, Ben-Chung Cheng4, Hong-Hwa Chen2, John Y Chiang5,6, Pei-Hsun Sung7,8, Hon-Kan Yip7,8,9,10,11.   

Abstract

BACKGROUND/AIM: We examined the hypothesis that T cell-derived-circulating microparticles (MPs) are increased in liver-cirrhosis (LC) patients compared to normal subjects and are also increased in chronic hepatitis compared to acute-decompensated-liver cirrhosis (ADLC). PATIENTS AND METHODS: A total of 66 LC patients, including 35 with ADLC and 31 with non-decompensated-LC (NDLC), were enrolled in the study. Ten volunteers served as controls.
RESULTS: Flow-cytometric analysis showed that circulating levels of T-cell derived MPs (i.e., total MPs and CD4+/CD8+/CD54+MPs) were higher in LC patients than in the controls (all p<0.003). Total MPs and CD8+MPs were higher in NDLC than in ADLC patients. There were good correlations between CD8+MPs and ADLC as well as between total MPs and chronic hepatitis. Multivariate-linear-regression analysis showed that NDLC was independently predictive of increased circulating CD8+MPs levels (p<0.05) and chronic hepatitis independently predictive of increased circulating total MPs levels (p<0.001)/CD4+MPs (p<0.05).
CONCLUSION: Circulating levels of T-cell-derived MPs were increased in ADLC patients and were even more elevated in NDLC patients compared to healthy-control subjects. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Circulating T-cell derived microparticles; inflammation; liver cirrhosis

Mesh:

Year:  2019        PMID: 31662566      PMCID: PMC6899156          DOI: 10.21873/invivo.11732

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  32 in total

Review 1.  Liver pathology: cirrhosis, hepatitis, and primary liver tumors. Update and diagnostic problems.

Authors:  L Ferrell
Journal:  Mod Pathol       Date:  2000-06       Impact factor: 7.842

Review 2.  Pathogenesis of liver fibrosis.

Authors:  Virginia Hernandez-Gea; Scott L Friedman
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

Review 3.  Hepatic stellate cells and liver fibrosis.

Authors:  Juan E Puche; Yedidya Saiman; Scott L Friedman
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

4.  [Epidemiology and natural history of cirrhosis].

Authors:  Sylvie Naveau; Gabriel Perlemuter; Axel Balian
Journal:  Rev Prat       Date:  2005-09-30

5.  Current status of novel antifibrotic therapies in patients with chronic liver disease.

Authors:  Michal Cohen-Naftaly; Scott L Friedman
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

6.  Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis.

Authors:  I R Wanless; E Nakashima; M Sherman
Journal:  Arch Pathol Lab Med       Date:  2000-11       Impact factor: 5.534

Review 7.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

8.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

9.  Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness.

Authors:  Hamish A Innes; Sharon J Hutchinson; Stephen Barclay; Elaine Cadzow; John F Dillon; Andrew Fraser; David J Goldberg; Peter R Mills; Scott A McDonald; Judith Morris; Adrian Stanley; Peter Hayes
Journal:  Hepatology       Date:  2013-01-08       Impact factor: 17.425

Review 10.  Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine.

Authors:  Tsang Lau; Jawad Ahmad
Journal:  Hepat Med       Date:  2013-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.